Cytovia Therapeutics, Inc., and Cellectis announced on February 16th that they have entered into a strategic research and development collaboration to develop TALEN® gene-edited iPSC NK and CAR-NK cells. The financial terms of the partnership include up to $760 million of development, regulatory, and sales milestones from Cytovia to Cellectis for the first 5 TALEN® gene-edited iPSC-derived NK products (“partnership products”). Cellectis will also receive single-digit royalty payments on the net sales of all partnered products commercialized by Cytovia. Cellectis will receive an equity stake of $15 million in Cytovia stock or an upfront cash payment of $15 million if certain conditions are not met by December 31, 2021, as well as an option to invest in future financing rounds.
For further information, see Cellectis (https://www.cellectis.com/en/press/cytovia-therapeutics-and-cellectis-partner-to-develop-talen-gene-edited-ipsc-derived-natural-killer-cells/)